Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Keisuke OnoiTadaaki YamadaKenji MorimotoHayato KawachiRei TsutsumiTakayuki TakedaAsuka OkadaNobuyo TamiyaYusuke ChiharaShinsuke ShiotsuYoshizumi TakemuraTakahiro YamadaIsao HasegawaYuki KatayamaMasahiro IwasakuShinsaku TokudaKoichi TakayamaPublished in: Targeted oncology (2024)
These findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events.